Ascendis Pharma A/S
ASND
96 hedge funds and large institutions have $2.85B invested in Ascendis Pharma A/S in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 15 closing their positions.
332% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $5.23M
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
8% more capital invested
Capital invested by funds: $2.63B → $2.85B (+$218M)
0.74% more ownership
Funds ownership: 95.31% → 96.05% (+0.74%)
6% less funds holding
Funds holding: 102 → 96 (-6)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.9M |
| 2 |
LCM
Lakewood Capital Management
New York
|
+$23.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.5M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$11.3M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25.9M |
| 2 |
Millennium Management
New York
|
-$24.2M |
| 3 |
O
OrbiMed
New York
|
-$17.7M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$16.5M |
| 5 |
DM
Deerfield Management
New York
|
-$11.2M |
ASND Hedge Fund Activity: Q3 2018 in Review
96 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2018, worth a combined $2.85B — up 8.3% from $2.63B a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ASND and 9 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 40 added.
The largest buyer was Fidelity Investments, adding an estimated $55.9M. The largest seller was EcoR1 Capital, cutting an estimated $25.9M.
- 96 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2018, down from 102 in Q2 2018.
- Funds reported $2.85B of Ascendis Pharma A/S stock for Q3 2018, up 8.3% quarter-over-quarter.
- 9 funds opened new Ascendis Pharma A/S positions in Q3 2018 and 15 closed out, a net change of -6 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2018 was Fidelity Investments, an estimated $55.9M added.
- The largest Ascendis Pharma A/S seller in Q3 2018 was EcoR1 Capital, an estimated $25.9M sold.
Based on aggregated 13F filings for Q3 2018.